Astellas Buys Iveric Bio for $5.9 Billion to Bolster Ophthalmology Portfolio

Published on : Published by : Mark Terry

Astellas Buys Iveric Bio for $5.9 Billion to Bolster Ophthalmology Portfolio By Mark TerryMay 2, 2023 Tokyo-based Astellas Pharma is buying Parsippany, NJ’s Iveric Bio for $5.9 billion. Iveric Bio [….]